Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
Authors
Keywords
-
Journal
MOVEMENT DISORDERS
Volume 28, Issue 2, Pages 131-144
Publisher
Wiley
Online
2012-12-06
DOI
10.1002/mds.25273
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial
- (2012) Caroline Moreau et al. LANCET NEUROLOGY
- Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
- (2012) P. A. LeWitt et al. NEUROLOGY
- Caffeine for treatment of Parkinson disease: A randomized controlled trial
- (2012) R. B. Postuma et al. NEUROLOGY
- Pardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial
- (2012) O. Rascol et al. PARKINSONISM & RELATED DISORDERS
- Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease
- (2011) Anil Kachroo et al. ANNALS OF NEUROLOGY
- Catechol-O-Methyltransferase Valine158Methionine Polymorphism Moderates Methylphenidate Effects on Oppositional Symptoms in Boys with Attention-Deficit/Hyperactivity Disorder
- (2011) Angélica Salatino-Oliveira et al. BIOLOGICAL PSYCHIATRY
- Istradefylline for the treatment of Parkinson's disease
- (2011) Ariane Park et al. EXPERT OPINION ON PHARMACOTHERAPY
- Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
- (2011) Robert A Hauser et al. LANCET NEUROLOGY
- AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial
- (2011) Peter A LeWitt et al. LANCET NEUROLOGY
- Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease
- (2011) Andrew Lees et al. MOVEMENT DISORDERS
- A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease
- (2011) Kitty K. Wong et al. MOVEMENT DISORDERS
- Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials
- (2011) Cristina Sampaio et al. MOVEMENT DISORDERS
- A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
- (2011) Fabrizio Stocchi et al. MOVEMENT DISORDERS
- Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study
- (2011) Robert D. Altman et al. MOVEMENT DISORDERS
- The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease
- (2011) Klaus Seppi et al. MOVEMENT DISORDERS
- AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials
- (2011) Daniela Berg et al. MOVEMENT DISORDERS
- The interplay of cholinergic function, attention, and falls in Parkinson's disease
- (2011) Alison Yarnall et al. MOVEMENT DISORDERS
- Methylphenidate for gait impairment in Parkinson disease: A randomized clinical trial
- (2011) A. J. Espay et al. NEUROLOGY
- Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease
- (2011) Marie Therese Armentero et al. PHARMACOLOGY & THERAPEUTICS
- The serotonergic system in Parkinson's disease
- (2011) Philippe Huot et al. PROGRESS IN NEUROBIOLOGY
- Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease
- (2010) Carine Karachi et al. JOURNAL OF CLINICAL INVESTIGATION
- Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial
- (2010) Martin Wolz et al. JOURNAL OF NEURAL TRANSMISSION
- Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease
- (2010) K. J. Black et al. JOURNAL OF NEUROSCIENCE
- Nicotinic Receptor-Mediated Reduction in L-DOPA-Induced Dyskinesias May Occur via Desensitization
- (2010) T. Bordia et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease
- (2010) Juliana Bronzova et al. MOVEMENT DISORDERS
- Effect of histamine H2receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease
- (2010) Tom H. Johnston et al. MOVEMENT DISORDERS
- Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease
- (2010) P. Stathis et al. MOVEMENT DISORDERS
- Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study
- (2010) Yoshikuni Mizuno et al. MOVEMENT DISORDERS
- Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease
- (2010) K. A. Chung et al. NEUROLOGY
- A long-term study of istradefylline in subjects with fluctuating Parkinson's disease
- (2010) Stewart Factor et al. PARKINSONISM & RELATED DISORDERS
- Single-Dose Administration of MK-0657, an NR2B-Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease
- (2009) Carol Addy et al. JOURNAL OF CLINICAL PHARMACOLOGY
- NMDA antagonist memantine improves levodopa-induced dyskinesias and “On-off” phenomena in Parkinson's disease
- (2009) Sara Varanese et al. MOVEMENT DISORDERS
- Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinsonʼs disease: an observational study
- (2009) Emmanuel Itti et al. NUCLEAR MEDICINE COMMUNICATIONS
- P2.109 Piclozotan reduces dyskinesia and OFF time in Parkinson's disease (PD) patients with L-dopa induced motor complications
- (2009) R.A. Hauser et al. PARKINSONISM & RELATED DISORDERS
- Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial
- (2009) H.H. Fernandez et al. PARKINSONISM & RELATED DISORDERS
- Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)
- (2008) Peter A. LeWitt et al. ANNALS OF NEUROLOGY
- Tesofensine (NS 2330), a Monoamine Reuptake Inhibitor, in Patients With Advanced Parkinson Disease and Motor Fluctuations
- (2008) Olivier Rascol ARCHIVES OF NEUROLOGY
- Serotonin Receptors
- (2008) David E. Nichols et al. CHEMICAL REVIEWS
- Continuous and Intermittent Nicotine Treatment Reduces L-3,4-Dihydroxyphenylalanine (L-DOPA)-Induced Dyskinesias in a Rat Model of Parkinson's Disease
- (2008) T. Bordia et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
- (2008) Robert A. Hauser et al. MOVEMENT DISORDERS
- Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism
- (2008) John G. Nutt et al. MOVEMENT DISORDERS
- Nicotine and Parkinson's disease: Implications for therapy
- (2008) Maryka Quik et al. MOVEMENT DISORDERS
- A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
- (2008) M. Stacy et al. NEUROLOGY
- Weight Loss Produced by Tesofensine in Patients With Parkinson's or Alzheimer's Disease
- (2008) Arne Astrup et al. Obesity
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now